IMUNON to Report Topline Results from the Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer Tomorrow

Results to be announced at 8:00 a.m. Eastern time , conference call to begin at 8:30 a.m. Eastern time LAWRENCEVILLE, N.J. , July 29, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN ), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, will issue a news release announcing topline results from the Phase 2 OVATION 2 Study with IMNN-001 in patients with advanced ovarian cancer tomorrow, July 30 , at approximately 8:00 a.m. Eastern time , and will host an investment community conference call to discuss the results and answer questions at 8:30 a.m. Eastern time . IMNN-001 is the Company’s interleukin-12 (IL-12) immunotherapy based on its TheraPlas ™ technology. To participate in the conference call, please dial 833-816-1132 (Toll-Free/ North America ) or 412-317-0711 (International/Toll) and ask for the IMUNON call. A live webcast of the call will be available here . Participants are encouraged to preregister for the call here . The call will be archived for replay through August 13, 2024 . The replay can be accessed at 877-344-7529 ( U.S. Toll-Free), 855-669-9658 (Canada Toll-Free) or 412-317-0088 (International Toll), using the replay access code 7783601. A webcast of the call will be available here for 90 days. About IMUNON IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas ® , is developed for the coding of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine ® , is developed for the delivery of DNA-coded viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101). IMUNON will continue to leverage these modalities and to advance the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information, please visit www.imunon.com . Contacts: IMUNON LHA Investor Relations David Gaiero Kim Sutton Golodetz 978-376-6352 212-838-3777 [email protected] [email protected] # # # Source: Imunon, Inc.

The release as fetched from its publisher. imunon.com ↗